Matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in invasive ductal carcinoma of the breast

Pathology Research and Practice

Volumn 207, Issue 12, 2011, Pages 747-753

  Sullu, Yurdanur ^a   Demirag, Guzin G ^a   Yildirim, Arzu ^b   Karagoz, Filiz ^a   Kandemir, Bedri ^a  

^a ONDOKUZ MAYIS UNIVERSITY   (Turkey)

^b Bayburt State Hospital   (Turkey)

Author keywords

Breast; Invasive ductal carcinoma; Matrix matalloproteinase 2; Matrix metalloproteinase 9; Triple negative breast carcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GELATINASE A; PROGESTERONE RECEPTOR; STROMELYSIN;

ADULT; ARTICLE; BREAST CARCINOGENESIS; CANCER GRADING; CANCER INVASION; CANCER SIZE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SURVIVAL TIME; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGED; AGED, 80 AND OVER; BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; GELATINASES; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHATIC METASTASIS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 82655178041     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2011.09.010     Document Type: Article

References (46)

1. Abbas Abidi S.M., Howard E.W., Dmytryk J.J., Pento J.T. Differential influence of antiestrogens on the in vitro release of gelatinases (type IV collagenases) by invasive and non-invasive breast cancer cells. Clin. Exp. Metastasis 1997, 15:432-439.
2. Allgayer H., Babic R., Gruetzner K.U., Tarabichi A., Schildberg F.W., Heiss M.M. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J. Clin. Oncol. 2000, 18:2201-2209.
3. Bauer K.R., Brown M., Cress R.D., Parise C.A., Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype. A population-based study from the California Cancer Registry. Cancer 2007, 109:1721-1728.
4. Beaudeux J.L., Giral P., Bruckert E., Foglietti M.J., Chapman M.J. Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives. Clin. Chem. Lab. Med. 2004, 42:121-131.
5. Benz C.C. Transcriptional factors and breast cancer. Endocr. Relat. Cancer 1998, 5:271-282.
6. Berney C.R., Yang J., Fisher R.J., Russell P.J., Crowe P.J. Correlates of urokinase-type plasminogen activator in colorectal cancer: positive relationship with nm23 and c-erbB-2 protein expression. Oncol. Res. 1998, 10:47-54.
7. A. Caldarella, E. Crocetti, S. Bianchi, V. Vezzosi, C. Urso, M. Biancalani, M. Zappa, Female breast cancer status according to ER, PR and HER2 expression: a population based analysis, Pathol. Oncol. Res., doi:10.1007/s12253-011-9381-z.
8. Curran S., Murray G.I. Matrix metalloproteinases in tumour invasion and metastasis. J. Pathol. 1999, 189:300-308.
9. Daniele A., Zito A.F., Giannelli G., Divella R., Asselti M., Mazzocca A., Paradiso A., Quaranta M. Expression of metalloproteinases MMP-2 and MMP-9 in sentinel lymph node and serum of patients with metastatic and non-metastatic breast cancer. Anticancer Res. 2010, 30:3521-3527.
10. Decock J., Hendrickx W., Wildiers H., Christiaens M.R., Neven P., Drijkoningen M., Paridaens R. Plasma gelatinase levels in patients with primary breast cancer in relation to axillary lymph node status, Her2/neu expression and other clinicopathological variables. Clin. Exp. Metastasis 2005, 22:495-502.
11. D'Errico A., Garbisa S., Castronovo R., Stetler-Stevenson W.G., Liotta L.A., Grigioni W.F. Augmentation of type IV collagenase and laminin receptors immunoreactivity associated with human breast, colon and gastric carcinoma progression. Mod. Pathol. 1991, 4:239-246.
12. Duffy M.J., Maguire T.M., Hill A., McDermott E., O'Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2000, 2:252-257.
13. Duffy M.J., McCarthy K. Matrix metalloproteinases in cancer: prognostic markers and targets for therapy. Int. J. Oncol. 1998, 12:1343-1348.
14. Egeblad M., Werb Z. New functions of the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002, 2:161-174.
15. Fingleton B. Matrix metalloproteinases: roles in cancer and metastasis. Front. Biosci. 2006, 11:479-491.
16. Hirvonen R., Talvensaari-Mattila A., Paakko P., Turpeennienmi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) in T1-2N0 breast carcinoma. Breast Cancer Res. Treat. 2003, 77:85-91.
17. Hynes R.O. Metastatic potential: generic predisposition of the primary tumor or rare, metastatic variants or both?. Cell 2003, 113:821-823.
18. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global Cancer statistics, CA. Cancer J. Clin. 2011, 61. (Early View).
19. Jezierska A., Motyl T. Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review. Med. Sci. Monit. 2009, 15:RA32-RA40.
20. Kaya M., Yoshida K., Higashino F., Mitaka T., Ishii S., Fujinaga K. A singlets-related transcription factor, E1AF, confers invasive phenotype on human cancer cells. Oncogene 1996, 18:221-227.
21. Kim I.-Y., Yong H.-Y., Kang K.W., Moon A. Overexpression of ErbB2 induces of MCF10A human breast epithelial cells via MMP-9. Cancer Lett. 2009, 275:227-233.
22. La Rocca G., Pucci-Minafra I., Marrazzo A., Taormina P., Minafra S. Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera. Br. J. Cancer 2004, 90:1414-1421.
23. Li H.-C., Cao D.-C., Liu Y., Hou Y.-F., Wu J., Lu J.-S., Di G.-H., Li F.-M., Ou Z.-L., Jie C., Shen Z.-Z., Shao Z.-M. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res. Treat. 2004, 88:75-85.
24. Liotta L.A., Stetler-Stevenson W.G. Metalloproteinases and cancer invasion. Semin. Cancer Biol. 1990, 1:99-106.
25. Lopez-Otin C., Matrisian L.M. Emerging roles of proteaz in tumour suppression. Nat. Rev. Cancer 2007, 10:800-808.
26. Martin M.D., Matrisian L.M. The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev. 2007, 26:717-724.
27. McGowan P.M., Duffy M.J. Matrix metalloproteinase expression and outcome in patients with breast cancer: analysis of a published database. Ann. Oncol. 2008, 19:1566-1572.
28. Mizumoto H., Saito T., Ashihara K., Nishimura M., Tanaka R., Kudo R. Acceleration of invasive activity via matrix metalloproteinases by transfection of the estrogen receptor-alpha gene in endometrial carcinoma cells. Int. J. Cancer 2002, 100:401-406.
29. Overall C.M., Dean R.A. Degradomics: systems biology of the protease web. Pleiotropic roles of MMPs in cancer. Cancer Metastasis Rev. 2006, 25:69-75.
30. Pellikainen J.M., Ropponen K.M., Kataja V.V., Kellokoski J.K., Eskelinen M.J., Kosma V.M. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin. Cancer Res. 2004, 10:7621-7628.
31. Perou C.M., Sørlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., Fluge O., Pergamenschikov A., Williams C., Zhu S.X., Lønning P.E., Børresen-Dale A.L., Brown P.O., Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
32. Philips N., McFadden K. Inhibition of transforming growth factor-beta and matrix metalloproteinases by estrogen and prolactin in breast cancer cells. Cancer Lett. 2004, 206:63-68.
33. Pozzi A., Moberg P.E., Miles L.A., Wagner S., Soloway P., Gardner H. Elevated matrix metalloproteinase and angiostatin levels in integrin alpha 1 knockout mice. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:2202-2207.
34. Rahko E., Jukkola A., Melkko J., Paavo P., Bloigu R., Talvensaari-Mattila A., Turpeenniemi-Hujanen T. Matrix metalloprotainase-9 (MMP-9) immunoreactive protein has modest prognostic value in locally advanced breast carcinoma patients treated with an adjuvant antiestrogen therapy. Anticancer Res. 2004, 24:4247-4254.
35. Rakha E.A., El-Sayed M.E., Green A.R., Lee A.H., Robertson J.F., Ellis I.O. Prognostic markers in triple-negative breast cancer. Cancer 2007, 109:25-32.
36. Reis-Filho J.S., Tutt A.N.J. Triple negative tumours: a critical review. Histopathology 2008, 52:108-118.
37. Robins P., Pinder S., de Klerk N. Histological grading of breast carcinomas: a study of interobserved agreement. Hum. Pathol. 1995, 28:873-879.
38. Scoralis A., Karameris A., Arnogiannaki N., Ardavanis A., Bassilopoulos P., Trangas T., Talieri M. Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients. Br. J. Cancer 2001, 84:1488-1496.
39. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ulrich A., McGuine W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
40. Spitale A., Mazzola P., Soldini D., Mazzucchelli L., Bordoni A. Breast cancer classification according to imunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based from the South of Switzerland. Ann. Oncol. 2009, 20:628-635.
41. Sørlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Thorsen T., Quist H., Matese J.C., Brown P.O., Botstein D., Eystein Lønning P., Børresen-Dale A.L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:10869-10874.
42. Talvensaari-Mattila A., Pääkko P., Blanco-Sequeiros G., Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with the risk for a relapse in postmenopausal patients with node-positive breast carcinoma treated with antiestrogen adjuvant therapy. Breast Cancer Res. Treat. 2001, 65:55-61.
43. Talvensaari-Mattila A., Pääkkö P., Turpeenniemi-Hujanen T. MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma. Breast Cancer Res. Treat. 1999, 58:287-293.
44. Welch D.R., Steeg P.S., Rinker-Schaeffer C.W. Molecular biology of breast cancer metastasis. Genetic regulation of human breast carcinoma metastasis. Breast Cancer Res. 2000, 2:408-416.
45. Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., Dowsett M., Fitzgibbons P.L., Hanna W.M., Langer A., McShane L.M., Paik S., Pegram M.D., Perez E.A., Press M.F., Rhodes A., Sturgeon C., Taube S.E., Tubbs R., Vance G.H., van de Vijver M., Wheeler T.M., Hayes D.F. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 2007, 25:118-145.
46. Wu Z.S., Wu Q., Yang J.H., Wang H.Q., Ding X.D., Yang F., Xu X.C. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int. J. Cancer 2008, 122:2050-2056.